CA Patent

CA2639416C — Diagnostic test for susceptibility to b-raf kinase inhibitors

Assigned to F Hoffmann La Roche AG · Expires 2019-12-31 · 6y expired

What this patent protects

The present invention provides methods and reagents for the detection of a mutation in BRAF and methods of selecting patients for treatment of a B-Raf kinase inhibitor, such as a selective B-Raf kinase inhibitor

USPTO Abstract

The present invention provides methods and reagents for the detection of a mutation in BRAF and methods of selecting patients for treatment of a B-Raf kinase inhibitor, such as a selective B-Raf kinase inhibitor

Drugs covered by this patent

Patent Metadata

Patent number
CA2639416C
Jurisdiction
CA
Classification
—
Expires
2019-12-31
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.